Once daily niraparib approved by European Commission for first-line monotherapy maintenance treatment of adults with advanced ovarian cancer

Approval was based on the PRIMA study in which niraparib, a PARP [poly (ADP-ribose) polymerase] inhibitor, resulted in a 38% reduction in the risk of disease progression or death vs placebo in the overall population.

Source:

PharmaTimes